Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Clinical Utilization and Outcomes of Hypomethylating Agents and Venetoclax in Patients with Myelodysplastic Syndrome - a Multicenter Retrospective Analysis

Blood (2024) 144 (Supplement 1): 3206.

https://doi.org/10.1182/blood-2024-211623

Published: 2024

Journal Articles

Exploiting the CD200-CD200R immune checkpoint axis in multiple myeloma to enhance CAR T-cell therapy

Blood (2024) 143 (2): 139–151.

https://doi.org/10.1182/blood.2022018658

Published: 2024

Includes: Supplemental data

Journal Articles

Characteristics and Outcomes of Younger Adult Patients (Pts) with Myelodysplastic Syndromes (MDS): A Multicenter Retrospective Study

Blood (2023) 142 (Supplement 1): 3232.

https://doi.org/10.1182/blood-2023-188328

Published: 2023

Journal Articles

Single-Agent Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple Myeloma: Final Analysis of the DREAMM-2 Trial

Blood (2022) 140 (Supplement 1): 7301–7303.

https://doi.org/10.1182/blood-2022-164877

Published: 2022

Journal Articles

A randomized phase 2 trial of idiotype vaccination and adoptive autologous T-cell transfer in patients with multiple myeloma

Blood (2022) 139 (9): 1289–1301.

https://doi.org/10.1182/blood.2020008493

Published: 2022

Includes: Supplemental data

Journal Articles

A Multicenter Phase II Clinical Trial of Rituximab Combined with Bortezomib (VELCADE®) Therapy for Untreated “High Tumor Burden” Indolent Non-Hodgkin Lymphoma (NHL)

Andrew M. Evens, DO, MSc, Mitchell R Smith, MD, PhD, Izidore S Lossos, MD, Borko Jovanovic, PhD, Adam Cohen, MD, Jane N. Winter, MD, Steven T. Rosen, MD, FRCPA, Leo I. Gordon, MD

Blood (2012) 120 (21): 1642.

https://doi.org/10.1182/blood.V120.21.1642.1642

Published: 2012

Journal Articles

The Novel KSP Inhibitor ARRY-520 Is Active Both with and without Low-Dose Dexamethasone in Patients with Multiple Myeloma Refractory to Bortezomib and Lenalidomide: Results From a Phase 2 Study

Jatin J. Shah, M.D., Jeffrey A. Zonder, MD, Adam Cohen, MD, William Bensinger, MD, Jonathan L. Kaufman, MD, Robert Z. Orlowski, M.D., Ph.D., R. Donald Harvey, PharmD, Muneer H. Abidi, MD, Sheeba K. Thomas, MD, Duncan Walker, PhD, Brandi Hilder, Ann Marie Ptaszynski, MD, Sagar Lonial, MD

Blood (2012) 120 (21): 449.

https://doi.org/10.1182/blood.V120.21.449.449

Published: 2012

Journal Articles

Feasibility of Electronic Directly Observed Therapy for Pediatric Leukemia Patients

Adam Cohen, Lakshmanan Krishnamurti, MD, Susan E. Creary, MD

Blood (2012) 120 (21): 3538.

https://doi.org/10.1182/blood.V120.21.3538.3538

Published: 2012

Journal Articles

The Novel KSP Inhibitor ARRY-520 Demonstrates Single-Agent Activity in Refractory Myeloma: Results From a Phase 2 Trial in Patients with Relapsed/Refractory Multiple Myeloma (MM)

Sagar Lonial, MD, Adam Cohen, Jeffrey Zonder, MD, William I Benzinger, MD, Jonathan L. Kaufman, MD, Robert Z. Orlowski, MD, PhD, R. Donald Harvey, PharmD, Raymond Alexanian, M.D., Sheeba K Thomas, M.D., Donna Weber, MD, Duncan Walker, PhD, Brandi Hilder, PhD, Ann Ptaszynski, Jatin J Shah, MD

Blood (2011) 118 (21): 2935.

https://doi.org/10.1182/blood.V118.21.2935.2935

Published: 2011

Journal Articles

ARRY-520 Shows Durable Responses in Patients with Relapsed/Refractory Multiple Myeloma in a Phase 1 Dose-Escalation Study

Jatin J Shah, MD, Jeffrey Zonder, MD, Adam Cohen, Robert Z. Orlowski, MD, PhD, Raymond Alexanian, M.D., Sheeba K Thomas, M.D., Donna Weber, MD, Jonathan L. Kaufman, MD, R. Donald Harvey, PharmD, Duncan Walker, PhD, Kevin Litwiler, PhD, Sharon Karan, Brandi Hilder, Ann Marie Ptaszynski, MD, Sagar Lonial, MD

Blood (2011) 118 (21): 1860.

https://doi.org/10.1182/blood.V118.21.1860.1860

Published: 2011

Journal Articles

Maintained Hematologic and Organ Responses at Two Years Following Stem Cell Transplant In Systemic Light-Chain Amyloidosis (AL) Using Short-Course Bortezomib and Dexamethasone Consolidation Therapy

Heather Landau, MD, Hani Hassoun, MD, Michael A. Rosenzweig, MD, Christina Bello, Elizabeth Hoover, Elyn Riedel, Alex Lesokhin, MD, Nikoletta Lendvai, MD, PhD, Adam Cohen, MD, Stephen Nimer, Raymond L. Comenzo, MD

Blood (2010) 116 (21): 2391.

https://doi.org/10.1182/blood.V116.21.2391.2391

Published: 2010

Journal Articles

Outcomes Following Salvage Autologous Stem Cell Transplant for Multiple Myeloma

Daniel E Fein, Hani Hassoun, MD, Raymond L. Comenzo, MD, Alex Lesokhin, Nikoletta Lendvai, MD, PhD, David Chung, MD, PhD, Adam Cohen, Michael A. Rosenzweig, MD, Danielle Chimento, Xiaoyu Jia, Stephen Nimer, Sergio Giralt, MD, Heather Landau, MD

Blood (2010) 116 (21): 1353.

https://doi.org/10.1182/blood.V116.21.1353.1353

Published: 2010

Journal Articles

A Phase I/II Trial of the KSP Inhibitor ARRY-520 In Relapsed/Refractory Multiple Myeloma

Jatin J Shah, MD, Jeffrey A. Zonder, MD, Adam Cohen, Donna Weber, MD, Sheeba Thomas, MD, Michael Wang, MD, Jonathan L. Kaufman, MD, Steven Michael Burt, Duncan Walker, Burgess Freeman, Selena Armistead Rush, BS, Ann Ptaszynski, Robert Z. Orlowski, MD, PhD, Sagar Lonial, MD

Blood (2010) 116 (21): 1959.

https://doi.org/10.1182/blood.V116.21.1959.1959

Published: 2010

Journal Articles

Early Adjuvant Treatment after Risk-Adapted Autologous Stem Cell Transplant for Systemic Light-Chain Amyloidosis: Increased Hospitalizations and Impaired Immune Recovery but Improved Responses and Overall Survival.

James E. Hoffman, MD, Hani Hassoun, MD, Heather Landau, MD, Elizabeth Hoover, Adam Cohen, MD, Stephen Nimer, MD, Raymond Comenzo, MD

Blood (2008) 112 (11): 3329.

https://doi.org/10.1182/blood.V112.11.3329.3329

Published: 2008

Journal Articles

Sequential Administration of Bortezomib, Liposomal Doxorubicin and Dexamethasone (BDD) Followed by Thalidomide and Dexamethasone (TD) Results in Rapid Control of Untreated High-Risk Multiple Myeloma (MM) and Improves Depth of Response

Heather Landau, MD, Hani Hassoun, MD, Adam Cohen, MD, Elizabeth Hoover, Tarun Kewalramani, MD, Adam Boruchov, MD, Virginia Klimek, MD, Lillian Reich, MD, Elyn Riedel, Neeta Pandit-Taskar, MD, Stephen D. Nimer, MD, Raymond L. Comenzo, MD

Blood (2008) 112 (11): 3712.

https://doi.org/10.1182/blood.V112.11.3712.3712

Published: 2008

Journal Articles

Efficacy and Long Term Survival of Genetically Modified T Cells Targeting CD19 in a Syngeneic Immune Competent Transgenic Murine Tumor Model Is Dependent on Prior Lymphodepleting Chemotherapy.

James Lee, BA, Yan Nikhamin, MS, Gavin Imperato, MS, Adam Cohen, MD, Michel Sadelain, MD/PhD, Renier Brentjens, MD/PhD

Blood (2007) 110 (11): 2754.

https://doi.org/10.1182/blood.V110.11.2754.2754

Published: 2007

Journal Articles

High Dose Chemotherapy and Autologous Stem Cell Transplantation with Melphalan in Patients with Monoclonal Immunoglobulin Deposition Disease Associated with Multiple Myeloma.

Hani Hassoun, MD, Brian T. Rafferty, MS, Carlos Flombaum, MD, Vivette D. D’Agati, MD, Virginia M. Klimek, MD, Adam Cohen, MD, Adam Boruchov, MD, Tarun Kewalramani, MD, Lilian Reich, MD, Heather Landau, MD, Stephen D. Nimer, MD, Raymond Comenzo, MD

Blood (2007) 110 (11): 5113.

https://doi.org/10.1182/blood.V110.11.5113.5113

Published: 2007

Journal Articles

Predictors of Survival in De Novo Cardiac Amyloidosis.

Raymond L. Comenzo, MD, Mathew Maurer, MD, Adam Cohen, MD, Hani Hassoun, MD, Ping Zhou, PhD, Ping Lu, PhD, Martin Fleisher, PhD, Daniel Lebovic, MD, Julie Feldstein, MD, Richard Steingart, MD, Stephen D. Nimer, MD

Blood (2007) 110 (11): 2870.

https://doi.org/10.1182/blood.V110.11.2870.2870

Published: 2007

Journal Articles

The Serum Free Light Chain Ratio after One or Two Cycles of Treatment Is Highly Predictive of the Magnitude of Final Response in Patients Undergoing Initial Treatment for Multiple Myeloma.

Hani Hassoun, MD, Lilian Reich, MD, Virginia M. Klimek, MD, Madhav Dhodapkar, MD, Adam Cohen, MD, Tarun Kewalramani, MD, Elyn R. Riedel, MA, Cyrus V. Hedvat, MD, Julie Teruya-Feldstein, MD, Daniel A. Filippa, MD, Martin Fleisher, PhD, Stephen D. Nimer, MD, Raymond L. Comenzo, MD

Blood (2005) 106 (11): 3481.

https://doi.org/10.1182/blood.V106.11.3481.3481

Published: 2005

Journal Articles

DNA Immunization Against Melanoma Antigens Enhances Tumor Immunity in Mice Following Sub-Lethal Irradiation and Immune Reconstitution.

Adi Diab, MD, Vanessa M. Hubbard, Adam Cohen, MD, Deonka Huggins, Adam Kochman, Jose A. Guevarra, MD, Manuel Engelhorn, PhD, Jedd D. Wolchok, MD, PhD, Marcel van den Brink, MD, PhD, Alan N. Houghton, MD, Miguel-Angel Perales, MD

Blood (2004) 104 (11): 3057.

https://doi.org/10.1182/blood.V104.11.3057.3057

Published: 2004

NARROW

Clinical Utilization and Outcomes of Hypomethylating Agents and Venetoclax in Patients with Myelodysplastic Syndrome - a Multicenter Retrospective Analysis

Exploiting the CD200-CD200R immune checkpoint axis in multiple myeloma to enhance CAR T-cell therapy

Characteristics and Outcomes of Younger Adult Patients (Pts) with Myelodysplastic Syndromes (MDS): A Multicenter Retrospective Study

Single-Agent Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple Myeloma: Final Analysis of the DREAMM-2 Trial

A randomized phase 2 trial of idiotype vaccination and adoptive autologous T-cell transfer in patients with multiple myeloma

A Multicenter Phase II Clinical Trial of Rituximab Combined with Bortezomib (VELCADE®) Therapy for Untreated “High Tumor Burden” Indolent Non-Hodgkin Lymphoma (NHL)

The Novel KSP Inhibitor ARRY-520 Is Active Both with and without Low-Dose Dexamethasone in Patients with Multiple Myeloma Refractory to Bortezomib and Lenalidomide: Results From a Phase 2 Study

Feasibility of Electronic Directly Observed Therapy for Pediatric Leukemia Patients

The Novel KSP Inhibitor ARRY-520 Demonstrates Single-Agent Activity in Refractory Myeloma: Results From a Phase 2 Trial in Patients with Relapsed/Refractory Multiple Myeloma (MM)

ARRY-520 Shows Durable Responses in Patients with Relapsed/Refractory Multiple Myeloma in a Phase 1 Dose-Escalation Study

Maintained Hematologic and Organ Responses at Two Years Following Stem Cell Transplant In Systemic Light-Chain Amyloidosis (AL) Using Short-Course Bortezomib and Dexamethasone Consolidation Therapy

Outcomes Following Salvage Autologous Stem Cell Transplant for Multiple Myeloma

A Phase I/II Trial of the KSP Inhibitor ARRY-520 In Relapsed/Refractory Multiple Myeloma

Early Adjuvant Treatment after Risk-Adapted Autologous Stem Cell Transplant for Systemic Light-Chain Amyloidosis: Increased Hospitalizations and Impaired Immune Recovery but Improved Responses and Overall Survival.

Sequential Administration of Bortezomib, Liposomal Doxorubicin and Dexamethasone (BDD) Followed by Thalidomide and Dexamethasone (TD) Results in Rapid Control of Untreated High-Risk Multiple Myeloma (MM) and Improves Depth of Response

Efficacy and Long Term Survival of Genetically Modified T Cells Targeting CD19 in a Syngeneic Immune Competent Transgenic Murine Tumor Model Is Dependent on Prior Lymphodepleting Chemotherapy.

High Dose Chemotherapy and Autologous Stem Cell Transplantation with Melphalan in Patients with Monoclonal Immunoglobulin Deposition Disease Associated with Multiple Myeloma.

Predictors of Survival in De Novo Cardiac Amyloidosis.

The Serum Free Light Chain Ratio after One or Two Cycles of Treatment Is Highly Predictive of the Magnitude of Final Response in Patients Undergoing Initial Treatment for Multiple Myeloma.

DNA Immunization Against Melanoma Antigens Enhances Tumor Immunity in Mice Following Sub-Lethal Irradiation and Immune Reconstitution.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only